Understanding how a protein affects immune cell activation
Identification of BATF function and targets during NK cell activation
This study is looking at a protein called Batf to see how it helps natural killer (NK) cells, which are important for fighting infections and cancer, do their job better, with the hope that this could lead to new and improved treatments for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10494220 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called Batf in the activation of natural killer (NK) cells, which are crucial for fighting infections and cancer. The study aims to identify how Batf influences the genes that control NK cell growth, survival, and function when responding to viruses and tumors. By examining the signaling pathways that activate NK cells, researchers hope to uncover new insights into how these immune cells can be better utilized in therapies against diseases. Patients may benefit from improved understanding of NK cell responses, potentially leading to enhanced treatments for infections and cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions that affect NK cell function, such as viral infections or certain cancers.
Not a fit: Patients with conditions unrelated to NK cell activity or those who do not have immune system involvement may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for enhancing immune responses against infections and cancer.
How similar studies have performed: Previous research has shown promising results in understanding immune cell activation, making this approach both relevant and potentially impactful.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Kee, Barbara L. — University of Chicago
- Study coordinator: Kee, Barbara L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.